LIDDS has successfully completed the first steps in one of its projects assessing the feasibility of using the NanoZolid® drug delivery technology for intratumoral immunotherapy with positive results.
In one of LIDDS immune-oncology projects, an immune-stimulatory agent was successfully formulated using the NanoZolid drug delivery technology. Chemical analytical methods demonstrated that the agent had a very promising release profile from the drug formulation. In a second step, the NanoZolid formulated immune-stimulatory agent was tested in an immuno-oncology model of a aggressive/hard to treat cancer in mice. In this model, a single dose of the locally delivered immunotherapy significantly reduced tumour growth and increased survival in the treated animals compared to control animals.
This demonstrates that that the NanoZolid drug delivery technology can be leveraged to develop novel immunotherapies that can act locally or intratumorally.
A locally delivered immunotherapy has the potential to act either as a monotherapy or in combination with systemic immunotherapies e.g. checkpoint inhibitors. A successful combination treatment could significantly increase the response rates and efficacy rates of current immunotherapies.
A recent review article in the highly ranked journal Annals of Oncology (Impact Factor 11.855) highlights the unique opportunity of intratumoral treatments to increase the efficacy of immunotherapy while reducing the potential side-effects.
Results from the other preclinical feasibility studies are expected in the first quarter of 2018.
Immunotherapy for the treatment of cancer aims to activate and utilize the body's own immune system to recognize and attack tumors and cancer cells and is today the fastest growing and most promising area of cancer research.
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, firstname.lastname@example.org
LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 27 December 2017 at 08.50 CET.
LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid can be combined with both large and small pharmaceutical molecules. The company's most advanced project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North. Redeye AB is a certified adviser to LIDDS. For more information, go to liddspharma.com.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire